PSNL

Business Context and Reporting Period

Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Personalis develops and sells advanced cancer genomic testing services for precision oncology, personalized testing, and population sequencing. The company serves pharmaceutical companies, diagnostic firms, government entities (e.g., VA MVP), and clinical patients. It operates as a single reportable segment with a primary facility in Fremont, California.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 25% ($5.1 million) year-over-year. This was driven by:
  • Pharma Testing: Decreased 21% due to lower sample volumes from Moderna and price declines.
  • Enterprise Sales: Decreased 84% due to the winding down of the Natera project.
  • Population Sequencing: Decreased 41% due to planned lower sample processing for the VA MVP.
• Clinical Diagnostic Growth: Revenue increased 365% ($1.1 million) following Medicare coverage approvals for breast cancer (Nov 2025) and lung cancer (Feb 2026).
• Margin Compression: Gross margin collapsed to 1.8% from 34.9% in Q1 2025. Cost of revenue increased 13% despite lower revenue, primarily due to higher clinical diagnostic test costs where reimbursement rates currently lag behind service costs.
• Expense Increases:
  • SG&A: Increased 46% ($5.6 million), driven by a $2.4 million increase in Tempus sales and marketing expenses and higher personnel costs.
  • R&D: Increased 15% ($1.9 million) due to higher personnel and IT expenses.
• Cash Flow: Net cash used in operating activities increased to $22.5 million (from $18.0 million in Q1 2025). Net cash used in investing activities increased to $46.0 million, largely due to increased purchases of short-term investments.

Guidance, Outlook, and Risks

• Capital Resources: Management believes current cash and investments ($233.2 million) are sufficient to fund operations for at least the next 12 months. The company recently exhausted its $100 million ATM facility in Q1 2026.
• Strategic Focus: The company is prioritizing the commercialization of NeXT Personal Dx in the clinical market, leveraging a partnership with Tempus AI. It continues to invest in R&D to support clinical evidence generation and reimbursement efforts.
• Key Risks:
  • Customer Concentration: Top three customers (Merck, VA MVP, Moderna) accounted for 51% of Q1 2026 revenue. Loss of any major customer could materially impact results.
  • Reimbursement Uncertainty: While Medicare coverage was secured for breast and lung cancer, reimbursement rates may not cover costs, and coverage from private payors remains uncertain.
  • Profitability: The company has a history of losses and expects to incur significant losses for the foreseeable future. An accumulated deficit of $661.3 million existed as of March 31, 2026.
  • Cybersecurity: A security incident in December 2025 involving unauthorized access to a small number of email accounts and potential exposure of patient PHI was disclosed.

Investor Verification Checklist

• Reimbursement Rates: Verify if Medicare and private payor reimbursement rates for NeXT Personal Dx are sufficient to cover the high cost of revenue currently being incurred.
• Customer Retention: Monitor the status of contracts with top customers (Merck, Moderna, VA MVP) given the high concentration risk.
• ATM Facility Status: Confirm the status of future equity financing options, as the current $100 million ATM facility is fully utilized.
• Cybersecurity Remediation: Review the extent of the December 2025 data breach and the effectiveness of implemented security measures.
• Tempus Partnership: Assess the performance of the Tempus commercialization agreement and the associated $2.9 million in quarterly marketing expenses.